Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Huntington’s disease, Friedreich’s ataxia, Alzheimer’s Disease and neuropathic pain.
The Antibody Platform group at Voyager Therapeutics is looking for a highly motivated individual experienced in antibody discovery and engineering, who thrives in a team-oriented, fast-paced, and cross-disciplinary start-up biotech environment. The individual will be responsible for activities that include culture and cloning of hybridomas for monoclonal antibody production and characterization, screening of hybridoma clones, antibody V gene sequencing, and recombinant antibody expression, purification, and characterization. This position is located in Cambridge, MA.